Findings

What do systematic reviews say?

72 questions · 73 findings · 8 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 27 · 37%GRADE not reported 8 · 11%Very low 0 · 0%Low 9 · 12.3%Moderate 14 · 19.2%High 15 · 20.5%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Etanercept vs corticosteroids · Disease‐specific mortality (time to
  Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
  RR 0.51 [0.16, 1.63]
  1 study · 91 participants
  Low
Direct match · question page
- Etanercept vs corticosteroids · Adverse effects leading to discontinuation of SJS/TEN therapy ‐ not reported (see comments)
  Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Etanercept vs no etanercept · Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported
  Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Etanercept vs cyclosporin · Adverse effects leading to discontinuation of SJS/TEN therapy ‐ not reported
  Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Etanercept vs intravenous immunoglobulin (IVIG) · Adverse effects leading to discontinuation of SJS/TEN therapy ‐ not reported
  Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Etanercept vs no etanercept

Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs no etanercept

Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs no etanercept

Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs no etanercept

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs no etanercept

Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs corticosteroids

Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

Etanercept showed no clear difference in disease‐specific mortality (time to compared with corticosteroids (low certainty).

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
RR 0.51 [0.16, 1.63]
1 study · 91 participants
Low

Etanercept vs corticosteroids

Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs corticosteroids

Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs corticosteroids

Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs corticosteroids

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs intravenous immunoglobulin (IVIG)

Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs intravenous immunoglobulin (IVIG)

Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs intravenous immunoglobulin (IVIG)

Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs intravenous immunoglobulin (IVIG)

Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs intravenous immunoglobulin (IVIG)

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs cyclosporin

Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs cyclosporin

Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs cyclosporin

Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs cyclosporin

Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs cyclosporin

Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found